Daniel M. Heinrich

Gjovik, Norway

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 45 publications

Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC).

Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC).

Journal: European urology

Published: September 01, 2024

Overall Survival of Patients with Metastatic Renal Cell Carcinoma Following the Introduction of Targeted and Immunotherapies: A Norwegian Retrospective, Real-World Registry Data Study (RECON3).

Overall Survival of Patients with Metastatic Renal Cell Carcinoma Following the Introduction of Targeted and Immunotherapies: A Norwegian Retrospective, Real-World Registry Data Study (RECON3).

Journal: Cancer management and research

Published: August 09, 2024

Plain language summary of the results from the TALAPRO-2 study: Talazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancer.

Plain language summary of the results from the TALAPRO-2 study: Talazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancer.

Journal: Future oncology (London, England)

Published: July 12, 2024

Alkaline phosphatase decline and pain response as predictors of overall survival benefit in patients treated with radium-223: a post hoc analysis of the REASSURE study.

Alkaline phosphatase decline and pain response as predictors of overall survival benefit in patients treated with radium-223: a post hoc analysis of the REASSURE study.

Journal: British journal of cancer

Published: May 24, 2024

Lenvatinib plus Pembrolizumab Following Immune Checkpoint Inhibitor Treatment in Patients with Metastatic Clear Cell Renal Cell Carcinoma: Results from Study 111/KEYNOTE-146.

Lenvatinib plus Pembrolizumab Following Immune Checkpoint Inhibitor Treatment in Patients with Metastatic Clear Cell Renal Cell Carcinoma: Results from Study 111/KEYNOTE-146.

Journal: European urology

Published: January 11, 2024

Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial.

Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial.

Journal: Lancet (London, England)

Published: April 06, 2023

An international comparative analysis and roadmap to sustainable biosimilar markets.

An international comparative analysis and roadmap to sustainable biosimilar markets.

Journal: Frontiers in pharmacology

Published: March 17, 2023

Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022.

Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022.

Journal: European journal of cancer (Oxford, England : 1990)

Published: February 17, 2023

Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022.

Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022.

Journal: European urology

Published: October 24, 2022

A randomized, open-label, phase 3 trial of pembrolizumab plus epacadostat versus sunitinib or pazopanib as first-line treatment for metastatic renal cell carcinoma (KEYNOTE-679/ECHO-302).

A randomized, open-label, phase 3 trial of pembrolizumab plus epacadostat versus sunitinib or pazopanib as first-line treatment for metastatic renal cell carcinoma (KEYNOTE-679/ECHO-302).

Journal: BMC cancer

Published: August 05, 2022

Correction to: Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway.

Correction to: Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway.

Journal: Journal of translational medicine

Published: July 15, 2022

SARS-CoV-2 in companion animals: Do levels of SARS-CoV-2 seroconversion in pets correlate with those of pet's owners and with protection against subsequent SARS-CoV-2 infection?

SARS-CoV-2 in companion animals: Do levels of SARS-CoV-2 seroconversion in pets correlate with those of pet's owners and with protection against subsequent SARS-CoV-2 infection?

Journal: Virulence

Published: July 08, 2022

Showing 1-12 of 45

Last Updated: 09/26/2026